Investment Rating - The investment rating for the company is "Buy" and is maintained [9] Core Insights - The company's 2024 performance met expectations with a revenue of 1.594 billion yuan, representing a year-on-year growth of 19.19%. The net profit attributable to shareholders was 364 million yuan, up 16.11% year-on-year [6][12] - The traditional business segments showed steady growth, particularly in home respiratory machine components, which generated 1.089 billion yuan in revenue, a 25.58% increase year-on-year. The artificial cochlear implant components also saw a revenue of 135 million yuan, growing 18.74% year-on-year [2][12] - The second growth curve is gradually being realized, with other medical product components generating 103 million yuan in revenue, a year-on-year increase of 21.08% [2][12] - The blood glucose management segment has achieved large-scale production of the insulin injection pen project, with the core development of the "Meihao Pen" nearing completion [2][12] - The company has successfully established a global production capacity with the completion of the second phase of its factory in Malaysia, which alleviates capacity pressure from overseas business growth [12] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 1.594 billion yuan and a net profit of 364 million yuan. The first quarter of 2025 showed a revenue of 296 million yuan, a 5.05% increase year-on-year, but a net profit of 51.875 million yuan, down 10.62% year-on-year [6][12] Business Segments - Home respiratory machine components contributed significantly to revenue with 1.089 billion yuan, while artificial cochlear implant components brought in 135 million yuan. The blood glucose management segment is also progressing with the insulin injection pen project [2][12] Growth Projections - The company forecasts revenues of 1.926 billion yuan, 2.331 billion yuan, and 2.820 billion yuan for 2025, 2026, and 2027 respectively, with net profits projected at 439 million yuan, 542 million yuan, and 663 million yuan for the same years [12][16]

深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）已于2025年4月18 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于召开2024年年度股东大会的通 知》（公告编号：2025-026），为保护投资者权益，方便公司股东行使股东大会表决 权，现将有关事项再次提示如下： 一、召开会议的基本情况 1.股东大会届次：2024年年度股东大会 2.股东大会的召集人：公司董事会 证券代码：301363 证券简称：美好医疗 公告编号：2025-032 深圳市美好创亿医疗科技股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 3.会议召开的合法、合规性：本次会议召开符合有关法律、行政法规、部门规 章、规范性文件、深圳证券交易所业务规则和《公司章程》等的规定。 4.会议召开的日期、时间 （1）现场会议时间：2025年5月8日（星期四）下午14:00 （2）网络投票时间：2025年5月8日（星期四）。其中，通过深圳证券交易所交 易系统进行网络投票的时间为2025年5月8日上午9:15-9:25、9:30-1 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-031 深圳市美好创亿医疗科技股份有限公司 关于签订募集资金四方监管协议补充协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意深圳市美好创亿医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可〔2022〕1441 号）、深圳证券交易 所《关于深圳市美好创亿医疗科技股份有限公司人民币普通股股票在创业板上市 的通知》（深证上〔2022〕986 号）同意，深圳市美好创亿医疗科技股份有限公 司（以下简称"公司"）首次公开发行人民币普通股（A 股）股票 4,427 万股， 发行价格为 30.66 元/股，募集资金总额 1,357,318,200.00 元，扣除发行费用人民 币 132,529,143.83 元后，募集资金净额为 1,224,789,056.17 元。天健会计师事务 所（特殊普通合伙）已对公司首次公开发行股票的资金到位情况进行了审验，并 于 2022 年 9 月 30 日出具了《验资报告》（天健验〔2022〕3-101 ...

Group 1 - The company reported Q1 2025 revenue of 296 million yuan, a year-on-year increase of 5.05%, while net profit attributable to shareholders was 52 million yuan, a year-on-year decrease of 10.62% [1] - The decline in profit is attributed to increased share-based payment expenses from the incentive plan and higher strategic business investments [1] - The company's gross margin for Q1 2025 was 39.28%, up 0.99 percentage points year-on-year, while net margin was 17.54%, down 3.07 percentage points year-on-year [1] Group 2 - The company maintains strong relationships with key clients in the home respiratory and cochlear implant markets, focusing on new product development and deepening strategic partnerships [2] - The company is expanding its overseas production capacity, with its Malaysia facility successfully passing FDA registration, which supports its global supply chain needs [2] - The company aims to accelerate the development of new products in high-growth markets such as blood glucose management and cardiovascular diagnostics [2] Group 3 - Revenue projections for 2025-2027 are estimated at 2.036 billion, 2.563 billion, and 3.199 billion yuan, with year-on-year growth rates of 28%, 26%, and 25% respectively [3] - Expected net profit attributable to shareholders for 2025-2027 is projected to be 471 million, 600 million, and 761 million yuan, with growth rates of 29%, 27%, and 27% respectively [3] - The company's current stock price corresponds to a PE ratio of 21, 17, and 13 for 2025-2027, indicating strong growth potential and a favorable investment outlook [3]

截至2025年4月25日收盘，美好医疗(301363)报收于24.47元，下跌7.97%，换手率11.72%，成交量13.14 万手，成交额3.17亿元。 当日关注点 交易信息汇总 4月25日美好医疗的资金流向情况如下：主力资金净流入1273.24万元；游资资金净流出1222.04万元；散 户资金净流出51.2万元。 股本股东变化 美好医疗近期披露了股东户数变动情况，截至2025年4月18日，公司股东户数为9131户，相较于4月10日 增加了14户，增幅达到0.15%。同时，户均持股数量从上期的4.46万股减少到4.45万股，户均持股市值 为117.26万元。 业绩披露要点 根据美好医疗2025年一季报的数据，公司主营收入为2.96亿元，同比增长5.05%；然而，归母净利润为 5187.5万元，同比下滑10.62%；扣除非经常性损益后的净利润为4921.53万元，同比下降11.67%。此 外，公司的负债率为12.08%，投资收益为156.04万元，财务费用为-1297.74万元，毛利率为39.28%。 以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company reported 1Q25 revenue of 296 million RMB, a year-on-year increase of 5.1%, while net profit attributable to the parent company decreased by 10.6% [1]. - The company is expected to maintain rapid growth in its core business, with projected revenue growth of 20-25% for home respiratory machine components and approximately 20% for artificial cochlear implant components in 2025 [2]. - The report highlights that the company is a leading domestic precision medical device supplier with a diversified growth outlook, supported by stable long-term partnerships with key clients [4]. Financial Performance - In 1Q25, the company's expense ratios increased year-on-year, with sales, management, R&D, and financial expense ratios at 4.06%, 10.58%, 11.05%, and -4.39%, respectively [3]. - The gross profit margin for 1Q25 was 39.28%, showing a slight year-on-year increase of 0.99 percentage points [3]. - The report forecasts net profits attributable to the parent company for 2025-2027 to be 457.65 million, 562.98 million, and 681.45 million RMB, respectively, representing growth rates of 26%, 23%, and 21% [4][10]. Valuation - The target price for the company is set at 38.26 RMB, based on a 34x PE valuation for 2025, compared to a comparable company average of 25x [4][7]. - The closing price as of April 24 was 26.59 RMB, indicating significant upside potential [7].

Group 1 - The core viewpoint of the news is that Meihao Medical's stock has experienced a significant decline, with a closing price of 24.47 yuan, down 7.97%, and a rolling PE ratio of 27.83 times, which is below the industry average [1] - Meihao Medical's total market capitalization is 9.951 billion yuan, ranking 68th in the medical device industry, which has an average PE ratio of 45.11 times and a median of 33.83 times [1] - The company has seen a net inflow of 12.7324 million yuan in main funds on April 25, but has experienced an overall outflow of 33.829 million yuan over the past five days [1] Group 2 - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components and cochlear implant components [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 296 million yuan, a year-on-year increase of 5.05%, while net profit was 51.875 million yuan, a year-on-year decrease of 10.62%, with a gross profit margin of 39.28% [1]

证券代码：301363 证券简称：美好医疗 公告编号：2025-029 深圳市美好创亿医疗科技股份有限公司 第二届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届监事会 第十四次会议通知于2025年4月14日以书面、电话等方式送达全体监事，并于2025 年4月24日在公司会议室召开现场会议。本次会议由监事会主席黎莎女士主持， 会议应到监事3人，实到监事3人，会议的召集和召开符合《中华人民共和国公司 法》《公司章程》等相关规定。 二、监事会会议审议情况 经全体与会监事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于公司<2025 年第一季度报告>的议案》 特此公告。 深圳市美好创亿医疗科技股份有限公司监事会 公司监事对公司《2025年第一季度报告》进行了审核，全体监事认为《2025 年第一季度报告》真实、准确、完整地反映了公司2025年第一季度的财务状况和 经营成果，不存在虚假记载、误导性陈述和重大遗漏。 具体内容详见公司同日披露于 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-028 二、董事会会议审议情况 深圳市美好创亿医疗科技股份有限公司 经全体与会董事认真审议、充分讨论，会议审议并通过了以下议案： 第二届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届董事会 第十七次会议通知于 2025 年 4 月 14 日以书面、电子邮件及电话等方式送达全体 董事，并于 2025 年 4 月 24 日在公司会议室以现场结合通讯方式召开。会议应参 加董事 7 人，实际参会董事 7 人，其中王建新先生、梁永晔先生、吴学斌先生、 孙超先生以通讯方式参会。本次会议由董事长熊小川先生召集并主持。公司监事、 高级管理人员列席了本次会议。经全体与会董事确认，本次会议的召集、召开以 及审议程序符合《公司法》《公司章程》和《董事会议事规则》等有关规定，会 议形成的决议合法、有效。 （一）审议通过《关于公司<2025 年第一季度报告>的议案》 一、董事会会议召开情况 1、公司第二届董事会第十七次会议决议； （二 ...

Financial Performance - The company's revenue for Q1 2025 was ¥295,757,022.22, representing a 5.05% increase compared to ¥281,550,999.26 in the same period last year[4] - Net profit attributable to shareholders decreased by 10.62% to ¥51,874,993.62 from ¥58,039,870.20 year-on-year[4] - Basic and diluted earnings per share both decreased by 7.14% to ¥0.13 from ¥0.14 year-on-year[4] - Total operating revenue for the current period reached ¥295,757,022.22, an increase of 5.4% compared to ¥281,550,999.26 in the previous period[20] - Net profit for the current period was ¥51,874,993.62, a decrease of 10.0% from ¥58,039,870.20 in the previous period[21] - Basic earnings per share for the current period was ¥0.13, down from ¥0.14 in the previous period[22] Cash Flow - The net cash flow from operating activities plummeted by 97.98% to ¥1,509,899.67, down from ¥74,921,798.44 in the previous year[4] - Cash inflow from operating activities totaled $417,923,048.16, an increase from $299,924,478.89 in the previous period, representing a growth of approximately 39.4%[24] - Cash outflow from operating activities was $416,413,148.49, up from $225,002,680.45, indicating a rise of about 85.1%[25] - Net cash flow from operating activities decreased to $1,509,899.67 from $74,921,798.44, reflecting a decline of approximately 98%[25] - Cash inflow from investment activities amounted to $620,943,757.30, compared to $379,495,840.28 in the prior period, marking an increase of about 63.7%[25] - Net cash flow from investment activities was -$112,938,114.65, an improvement from -$332,218,844.82, indicating a reduction in cash outflow by approximately 66%[25] - Cash inflow from financing activities was $8,500,000.00, with no previous inflow reported[25] - Net cash flow from financing activities was -$4,812,312.16, worsening from -$1,875,130.18 in the previous period[25] - The ending balance of cash and cash equivalents was $703,604,951.22, a decrease from $935,304,050.79[25] Assets and Liabilities - Total assets increased by 2.15% to ¥4,005,917,773.80 compared to ¥3,921,612,493.46 at the end of the previous year[4] - Total liabilities increased to ¥484,038,229.01, compared to ¥441,955,306.48 in the previous period, marking a rise of 9.3%[18] - The company's total equity reached ¥3,521,879,544.79, an increase from ¥3,479,657,186.98 in the previous period, reflecting a growth of 1.2%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,334, with the largest shareholder holding 45.74% of the shares[11] - The company has completed a share repurchase plan, acquiring 2,368,840 shares, which represents 0.5825% of the total share capital, with a total expenditure of RMB 61,568,589.91[14] - The highest transaction price during the share repurchase was RMB 29.72 per share, while the lowest was RMB 22.80 per share[14] - The company plans to use between RMB 50 million and RMB 100 million for share repurchase to support employee stock ownership plans[14] Expenses and Investments - Research and development expenses rose by 43.84% to ¥32,674,593.72 from ¥22,716,655.12 in the previous year, indicating a focus on innovation[10] - Total operating costs increased to ¥246,494,069.60, up 13.6% from ¥216,931,034.93 in the previous period[20] - Investment income surged by 195.63% to ¥1,560,436.03, up from ¥527,840.49, reflecting improved financial management[10] - The company experienced a 312.33% increase in taxes and surcharges, amounting to ¥3,928,808.21, due to increased tax liabilities[10] Strategic Initiatives - The company has initiated a "Quality Return Dual Improvement" action plan aimed at enhancing investor confidence and promoting sustainable development[13] - The company is focused on maintaining the interests of all shareholders, particularly small and medium-sized investors, as part of its strategic initiatives[13] - The company is focusing on market expansion and new product development as part of its strategic initiatives moving forward[23] Other Financial Metrics - The company reported a total cash balance of RMB 1,220,372,277.91 as of March 31, 2025, down from RMB 1,252,273,385.93 at the beginning of the period, reflecting a decrease of approximately 2.54%[16] - The company's accounts receivable decreased to RMB 264,339,226.05 from RMB 344,626,321.14, indicating a decline of about 23.3%[16] - The company’s trading financial assets decreased to RMB 481,450,753.59 from RMB 491,733,204.65, a reduction of approximately 2.5%[16] - Other receivables increased significantly to RMB 102,460,141.31 from RMB 5,295,014.62, marking a substantial rise of over 1,837%[16] - The company’s prepayments decreased to RMB 10,611,293.21 from RMB 12,667,577.34, reflecting a decline of about 16.2%[16] Audit Status - The first quarter report for 2025 was not audited[27]